Champions Oncology Inc Q2 Earnings Revenue Surpasses Estimates at 13.5 Million
| CSBR Stock | USD 5.16 0.68 11.64% |
Slightly above 60% of Champions Oncology's investor base is looking to short. The analysis of overall sentiment of trading Champions Oncology stock suggests that many investors are alarmed at this time. Champions Oncology's investing sentiment overview a quick insight into current market opportunities from investing in Champions Oncology. Many technical investors use Champions Oncology stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Champions |
On December 11, 2024, Champions Oncology Inc released its 8-K filing detailing its financial results for the second quarter of fiscal 2025, ending Octobe
Read at gurufocus.com
 |
Champions Oncology Fundamental Analysis
We analyze Champions Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Champions Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Champions Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Champions Oncology is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Champions Oncology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Champions Oncology stock to make a market-neutral strategy. Peer analysis of Champions Oncology could also be used in its relative valuation, which is a method of valuing Champions Oncology by comparing valuation metrics with similar companies.
Peers
Champions Oncology Related Equities
| MOLN | Molecular Partners | 0.73 | ||||
| ANEB | Anebulo Pharmaceuticals | 0.72 | ||||
| ADAG | Adagene | 0.47 | ||||
| AVTE | Aerovate Therapeutics | 1.14 | ||||
| MNOV | MediciNova | 1.38 | ||||
| ELYM | Eliem Therapeutics | 1.90 | ||||
| HCWB | HCW Biologics | 2.50 | ||||
| ANTX | AN2 Therapeutics | 4.52 | ||||
| ACRV | Acrivon Therapeutics, | 5.65 | ||||
| RZLT | Rezolute | 6.07 | ||||
| IPSC | Century Therapeutics | 7.41 | ||||
| STTK | Shattuck Labs | 9.77 |
Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.